Voriconazole vs itraconazole for the primary prophylaxis of invasive fungal infections following allogenic haematopoietic stem cell transplant

Trial Profile

Voriconazole vs itraconazole for the primary prophylaxis of invasive fungal infections following allogenic haematopoietic stem cell transplant

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2011

At a glance

  • Drugs Itraconazole; Voriconazole
  • Indications Mycoses; Various toxicities
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMPROVIT
  • Most Recent Events

    • 07 Jun 2011 New trial record
    • 25 May 2011 Economic results for the first 100 days presented at the International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 10 May 2011 Economic results after the first 100 days presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top